Interleukin-2 (IL-2), an immunomodulatory cytokine that promotes T cell and natural killer (NK) cell activity has been tested extensively in the clinic in the 1980s and 1990s and induced long-term responses in a small group of melanoma patients, but also caused severe toxicities [2, 3]. This evidence concerns the gene IL2 and melanoma.